Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil

Am J Ophthalmol. 1988 Feb 15;105(2):155-9. doi: 10.1016/0002-9394(88)90179-1.


We investigated the effect of the calcium channel blocker verapamil on intraocular pressure in human volunteers. In the initial trial, 15 subjects with untreated ocular hypertension were tested. After a baseline measurement was obtained with applanation tonometry, a 40-microliter drop of verapamil, 1.25 mg/ml, was instilled in one eye. After 30 minutes, a second reading was taken. In a subsequent trial of 12 untreated ocular hypertensive subjects, the duration of action was determined using the same dose and method of delivery. Results showed that verapamil elicited a mean +/- S.E.M. change in intraocular pressure of -3.8 +/- 0.900 mm Hg in the treated eye, and -1.6 +/- 0.400 mm Hg in the untreated eye. This reduction was statistically different in both eyes (treated eye, P = .0007; untreated eye, P = .005). This decrease in intraocular pressure remained statistically significant when compared to predrug baseline values for up to ten hours.

MeSH terms

  • Administration, Topical
  • Circadian Rhythm
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Intraocular Pressure / drug effects*
  • Male
  • Middle Aged
  • Ocular Hypertension / drug therapy
  • Ocular Hypertension / physiopathology*
  • Ophthalmic Solutions
  • Verapamil / pharmacology*
  • Verapamil / therapeutic use


  • Ophthalmic Solutions
  • Verapamil